Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novo Nordisk signs GlucaGen marketing agreement with Bedford

Aug. 12, 1999

FDA further expands approved indications for Zocor

Aug. 11, 1999

Novo Nordisk, Takeda will collaborate on marketing of antidiabetic drugs in Japan

Aug. 11, 1999

Yamanouchi reports two new series of ICE inhibitors

Aug. 10, 1999

NexMed reports promising phase I results with drug for FSD

Aug. 10, 1999

U.S. study will investigate the effects of phytoestrogens on the human endometrium

Aug. 10, 1999

New family of ACAT inhibitors described by Merck KGaA

Aug. 9, 1999

Kinetek obtains patent protection for antidiabetic organovanadium compound

Aug. 9, 1999

Duramed files for approval of 1.25-mg strength Cenestin tablets

Aug. 9, 1999

Hokuriku Seiyaku's STAT5 activators are useful for regulating platelet production

Aug. 6, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...